Novartis Ag (NVS) Payables (2009 - 2026)

Novartis Ag has disclosed Payables across 18 years of filings, most recently posting $4.3 billion for Q2 2026.

• In Q2 2026, Payables fell 5.5% year-over-year to $4.3 billion; the TTM figure through Jun 2026 stood at $4.3 billion (down 5.5% YoY), while the FY2025 annual figure was $5.1 billion, down 1.46% from the prior year.
• Payables came in at $4.3 billion for Q2 2026 at Novartis Ag, down from $4.3 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $6.0 billion in Q4 2022 to a low of -$67.0 million in Q1 2022.
• Average Payables over 5 years is $4.5 billion, with a median of $4.5 billion recorded in 2025.
• Year-over-year, Payables tumbled 2133.33% in 2022 and soared 8198.51% in 2023.
• Over 5 years, Payables stood at $6.0 billion in 2022, then slipped by 7.64% to $5.6 billion in 2023, then fell by 6.05% to $5.2 billion in 2024, then dropped by 1.46% to $5.1 billion in 2025, then slipped by 17.13% to $4.3 billion in 2026.
• Per Business Quant data, the three most recent Payables figures were $4.3 billion in Q2 2026, $4.3 billion in Q1 2026, and $5.1 billion in Q4 2025.